Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.71 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutathione Ethyl Ester SCHEMBL9817298 | 1.00 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1KMT2A | |
| Glutathione Ethyl Ester SCHEMBL7530345 | 1.00 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1KMT2A | |
| Glutathione Ethyl Ester SCHEMBL8749892 | 0.99 | PTGS1 (0.70) | PTGS1GSTK1GLO1NOD1KMT2A | |
| Glutathione Ethyl Ester SCHEMBL7530375 | 0.96 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1KMT2A | |
| Glutathione Ethyl Ester SCHEMBL7527153 | 0.96 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1KMT2A | |
| Glutathione Ethyl Ester SCHEMBL7527777 | 0.96 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1KMT2A | |
| Glutathione Ethyl Ester SCHEMBL7526098 | 0.96 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1KMT2A | |
| SCHEMBL19293518 | 0.92 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1KMT2A | |
| SCHEMBL16501104 | 0.92 | PTGS1 (0.58) | PTGS1GSTK1GLO1NOD1KMT2A | |
| SCHEMBL2137598 | 0.92 | PTGS1 (0.58) | PTGS1GSTK1GLO1NOD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 842 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075706-A | Use of hyposulfonated glycogen synthase kinase-3 in the prevention and treatment of liver insulin resistance | — | 2026-05-26 | — | — | CN | claimed |
| CN-119320365-A | Benzoxazine derivative and preparation method, application and detection method thereof | 吕梁学院 | 2025-01-17 | — | — | CN | claimed |
| US-20240335410-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | UNIV CASE WESTERN RESERVE (US) | 2024-10-10 | — | — | US | claimed |
| US-20240325327-A1 | METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY | TRUSTEES OF DARTMOUTH COLLEGE | 2024-10-03 | — | — | US | claimed |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2023-12-12 | — | — | US | claimed |
| US-20230338319-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-26 | — | — | US | claimed |
| CN-111480080-B | Method for improving therapeutic cell quality by real-time glutathione measurement | 塞尔吐温株式会社 | 2023-09-19 | — | — | CN | claimed |
| CN-111138466-B | Preparation method of novel BODIPY dynamic fluorescent probe and application of living cells in real-time detection of glutathione concentration change | 南开大学 | 2023-01-17 | — | — | CN | claimed |
| EP-3719500-B1 | METHOD FOR IMPROVING QUALITY OF THERAPEUTIC CELL THROUGH REAL-TIME GLUTATHIONE MEASUREMENT | CELL2IN INC (KR) | 2023-01-04 | — | — | EP | claimed |
| US-20220257544-A1 | COMPOSITION AND METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY | TRUSTEES OF DARTMOUTH COLLEGE | 2022-08-18 | — | — | US | claimed |
| US-5846961-A | Multi-faceted method to repress reproduction of latent viruses in humans and animals | HIV DIAGNOSTICS, INC. (US) | 1998-12-08 | — | — | US | claimed |
| US-5780489-A | ADMINISTERING A NON-CYSTEINE GLUTATHIONE PRECURSOR OR A GLUTATHIONE DERIVATIVE TO INCREASE INTRACELLULAR GLUTATHIONE LEVELS; ALLEVIATES THE SYMPTOM OF MUSCULAR DEGENERATION | XANTHUS LIFE SCIENCES, INC. | 1998-07-14 | — | — | US | claimed |
| WO-1998029375-A1 | BRAIN TARGETED LOW MOLECULAR WEIGHT HYDROPHOBIC ANTIOXIDANT COMPOUNDS | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-09 | — | — | WO | claimed |
| EP-0784471-A4 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1997-11-19 | — | — | EP | claimed |
| US-5686436-A | SUPPRESSING HUMAN IMMUNODEFICIENCY VIRUS, FELINE IMMUNODEFICIENCY VIRUS, FELINE LEUKEMIA VIRUS | HIV DIAGNOSTICS, INC. (US) | 1997-11-11 | — | — | US | claimed |
| EP-0623342-B1 | Use of an alkyl ester of glutathione in a cosmetic or dermatological composition for the topical treatment of skin ageing | OREAL (FR) | 1997-09-17 | — | — | EP | claimed |
| EP-0784471-A2 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | Van Dyke, Knox (US) | 1997-07-23 | — | — | EP | claimed |
| WO-1996010402-A1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1996-04-11 | — | — | WO | claimed |
| WO-1994017799-A1 | METHOD FOR TREATING INFERTILITY | FREE RADICAL SCIENCES, INC. (US) | 1994-08-18 | — | — | WO | claimed |
| US-4879370-A | ALKYL ESTER TO INCREASE CELLULAR LEVELS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1989-11-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257544-A1 | COMPOSITION AND METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY | MAPT, LCAT, ACAT2 | PTGS1 960/4885GSTK1 442/4885GLO1 519/4885 |
| US-20240335410-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | GSTM1, GSTO1, GSR | PTGS1 378/4885GSTK1 8/4885GLO1 51/4885 |
| US-20240325327-A1 | METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY | MAPT, LCAT, ACAT2 | PTGS1 996/4885GSTK1 287/4885GLO1 513/4885 |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | GSR, GPX1, GGT1 | PTGS1 236/4885GSTK1 8/4885GLO1 37/4885 |
| US-20230338319-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | GSTM1, GSTO1, GSR | PTGS1 378/4885GSTK1 8/4885GLO1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.